FDA Approved: TYENNE — Supplemental Application (Fresenius Kabi USA, LLC)

View source ↗

Summary

FDA approved a supplemental application for TYENNE (tocilizumab-azg) from Fresenius Kabi USA, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome
• Giant Cell Arteritis
• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis
• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• TYENNE (TOCILIZUMAB-AAZG)

Snippet

SUPPL AP for TYENNE (TOCILIZUMAB-AAZG)